Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine
Details : hAd5 S+N is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublingual, and oral.
Brand Name : hAd5 S+N
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 08, 2021
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : CytRx Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 15, 2021
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : CytRx Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Details : The combination of NantKwest’s Natural Killer (NK) cell platform and ImmunityBio’s immunotherapy fusion protein, immunomodulator, and adenovirus platforms have already resulted in complete responses in late stage, difficult to treat metastatic cancer...
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aldoxorubicin HCl,N-803,PD-L1 t-haNK
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Details : The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NA...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : Aldoxorubicin HCl,N-803,PD-L1 t-haNK
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Developed by ImmunityBio and manufactured by NantKwest, this second generation hAd5-vector vaccine is unique in targeting both spike and nucleocapsid SARS-CoV-2 proteins. Low dose cohort reports no serious adverse events, high dose cohort safety analysis...
Brand Name : hAd5
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 10, 2020
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : First patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the corona...
Brand Name : hAd5
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 21, 2020
Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial
Details : Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist AnktivaÔ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancr...
Brand Name : PD-L1 t-haNK
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 06, 2020
Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BM-Allo.MSC
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 18, 2020
Lead Product(s) : BM-Allo.MSC
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 14, 2020
Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HaNK
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Collaboration
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting Covid-19
Details : Under this collaboration, NantKwest and ImmunityBio are combining their resources to design and develop therapeutics and vaccines for COVID-19.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 14, 2020
Lead Product(s) : HaNK
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?